BMY
Bristol-Myers Squibb Company (BMY) SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (BMY) Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (BMY) TD Cowen 46th Annual Health Care Conference
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Corporate Conference
Bristol-Myers Squibb Company (BMY) nnounces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (BMY) U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb Company (NYSE: BMY) FY 2026 Other Release
Bristol-Myers Squibb Company (BMY) Sec Form 10K
Bristol-Myers Squibb Company (NYSE: BMY) Sec Form 10K
Bristol-Myers Squibb Company (BMY) Sec Form 8K
Bristol-Myers Squibb Company (NYSE: BMY) Sec Form 8K